These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1973459)

  • 21. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.
    Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Price P; McKinna A; Harrison S
    Int J Cancer; 1988 Dec; 42(6):842-5. PubMed ID: 2903851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
    Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
    Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
    Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
    J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
    Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
    Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
    J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.
    Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM
    Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team.
    Evans AJ; Pinder SE; Ellis IO; Sibbering DM; Elston CW; Poller DN; Wilson AR
    Clin Radiol; 1994 Aug; 49(8):559-62. PubMed ID: 7955870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
    Barnes DM; Bartkova J; Camplejohn RS; Gullick WJ; Smith PJ; Millis RR
    Eur J Cancer; 1992; 28(2-3):644-8. PubMed ID: 1350456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.
    Bartkova J; Barnes DM; Millis RR; Gullick WJ
    Hum Pathol; 1990 Nov; 21(11):1164-7. PubMed ID: 1977679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunoexpression of c-erbB-2 in intraductal proliferative lesions of the female breast].
    Oliveira AB; De Luca LA; Carvalho GT; Arias VE; Carvalho LR; Assunção Mdo C
    Rev Assoc Med Bras (1992); 2004; 50(3):324-9. PubMed ID: 15499488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-erbB-2 expression in different histological types of invasive breast carcinoma.
    Soomro S; Shousha S; Taylor P; Shepard HM; Feldmann M
    J Clin Pathol; 1991 Mar; 44(3):211-4. PubMed ID: 1672872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rare expression of the c-erbB-2 oncoprotein in salivary gland tumors: an immunohistochemical study.
    Shrestha P; Huang JW; Tsuji T; Shinozaki F; Maeda K; Sasaki K; Ueno K; Yamada K; Mori M
    J Oral Pathol Med; 1992 Nov; 21(10):477-80. PubMed ID: 1361005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.